Sigachi Laboratories Limited
52W HIGH
Rs 57.2
52W LOW
Rs 57.2
1Y RETURN
+0.0%
About the Company
Sigachi Laboratories Limited is an Indian pharmaceutical company referenced for manufacturing active ingredients and intermediates, complementing the broader Sigachi group known for excipients. Public materials cite capabilities in compliant production, quality control and customer documentation to support formulations and regulated-market needs. The company supplies domestic and select export customers, focusing on reliability, technical service and adherence to applicable standards.
Quick Facts
As of 7 Jul 2026
Quantity
Minimum investment Rs 1,00,000 (1,749 shares).
Settled in T+1 days. KYC verified dealers.
Get Sigachi Laboratories Limited's live price
Share a few details and our desk sends you the latest price, availability and how to invest.
Trusted by 5,000+ investors · your details are never shared.
FUNDAMENTALS
Key Indicators
A snapshot of Sigachi Laboratories Limited's valuation multiples and capital efficiency at a glance.
CURRENT SHARE PRICE
Rs 57.2
FACE VALUE / SHARE
Rs 10
BOOK VALUE / SHARE
Rs 58.39
PRICE TO EARNING (PE)
29.55
PRICE / BOOK
0.89
MARKET CAP
38.63 Cr
DEBT TO EQUITY
0.00
RETURN ON EQUITY
3.03%
52 WEEK HIGH
Rs 57.2
52 WEEK LOW
Rs 57.2
FINANCIALS
Fundamentals & Financial Statements
Price / Share
₹52
P/E Ratio
29.55
P/B Ratio
0.89
Debt to Equity
0.00
Book Value
₹58.39
Face Value
₹10
| Particulars | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 260 | 195 | 374 | 312 |
| Cost of Material Consumed | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Gross Margins | 100% | 100% | 100% | 100% |
| Employee Benefit Expenses | 34 | 36 | 39 | 43 |
| Other Expenses | 15 | 17 | 93 | 160 |
| EBITDA | 211 | 142 | 242 | 109 |
| OPM | 81.15% | 72.82% | 64.71% | 34.94% |
| Other Income | 44 | 50 | 62 | 66 |
| Finance Cost | 0 | 0 | 0 | 0 |
| Depreciation & Amortisation | 17 | 19 | 23 | 23 |
| EBIT | 194 | 123 | 219 | 86 |
| EBIT Margins | 74.62% | 63.08% | 58.56% | 27.56% |
| Profit Before Tax | 238 | 173 | 281 | 152 |
| PBT Margins | 91.54% | 88.72% | 75.13% | 48.72% |
| Tax | 38 | 42 | 84 | 33 |
| Profit After Tax | 200 | 131 | 197 | 119 |
| Net Profit Margin | 76.92% | 67.18% | 52.67% | 38.14% |
| EPS | ₹2.74 | ₹1.79 | ₹2.69 | ₹1.63 |
PROCESS
How to Buy Sigachi Laboratories Limited
Enquire
Share your requirement and preferred quantity with our desk.
Get a quote
Receive the latest indicative price, lot size and availability.
Complete KYC
Quick paperwork with a KYC-verified counterparty.
Receive shares
Shares credited to your demat, typically within T+1 days.
OWNERSHIP
Shareholding Pattern
Indicative ownership structure. Exact filed breakup confirmed at dealing.
CORPORATE CALENDAR
Events & Announcements
Typical annual calendar. Exact dates updated as the company announces them.
LEADERSHIP
Management Team
Standard governance structure. Named directors added as verified. Tap any role to see what they do and why it matters for investors.
REPORTS
Download Financial Results
Sigachi Laboratories Limited Financial Report
Fundamentals, financial statements and key ratios in one PDF
Need the official filed reports?
Get audited annual & quarterly filings (MCA / RTA) for Sigachi Laboratories Limited straight from our desk.
QUESTIONS
Frequently Asked Questions
NEWS & INSIGHTS
Latest on Sigachi Laboratories Limited & its sector
CORPORATE
Company Details
ISIN
INE368H01018
CIN
L24230TG1994PLC018786
PAN
AACCS8220M
REGISTRAR (RTA)
Venture Capital and Corporate Investments
DEPOSITORY
NSDL & CDSL
INCORPORATED
Nov 1994
OUTSTANDING SHARES
67,53,100
REGISTERED OFFICE
SY. NO. 530 & 534, TEMPLE ROAD, BONTHAPALLY VILLAGE, JINNARAM MANDAL, MEDAK DIST TG IN 000000, India
SECTOR
Health Care
INDUSTRY
Pharmaceuticals / Lab Services
READY TO INVEST?
Enquire with Neoma Capital
Talk to a CA advisor about Sigachi Laboratories Limited. Get pricing, availability, and transfer process guidance.
Disclaimer: Prices shown are indicative and for reference purposes only. Unlisted shares carry higher risk than listed equities. Past performance is not indicative of future results. Financial statements, where shown, are compiled from company filings (MCA / RTA) and may be restated in subsequent filings. Neoma Capital does not provide investment advice. Please consult a qualified financial advisor. Transactions subject to KYC verification and SEBI regulations.